# ETV4

Source: https://onco.cc/targets/etv4/  
OnCo record `etv4` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ETV4 (ETS translocation variant 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 1 more.

## Summary

Transcriptional activator. Regulates the positioning of motor neurons within the lateral medial column of the spinal cord and controls the terminal arborisation of specific motor neuron axons within their target muscles. Required for the expression of CDH8 and SEMA3E in ETV4-expressing motor neurons and for the exclusion of CDH7 expression from these neurons.

CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.99, animal model 0.41, genetic association 0.23, somatic mutation 0.97). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Neuroblastoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ETS variant transcription factor 4; ETS translocation variant 4; E1A-F; E1AF; PEA3
- Tags: cancer-genes-wave
- Symbol: ETV4
- Class: oncogene
- Biology: Transcriptional activator. Regulates the positioning of motor neurons within the lateral medial column of the spinal cord and controls the terminal arborisation of specific motor neuron axons within their target muscles. Required for the expression of CDH8 and SEMA3E in ETV4-expressing motor neurons and for the exclusion of CDH7 expression from these neurons. May play a role in keratinocyte differentiation. Location: Nucleus (UniProt). Locus 17q21.31 (HGNC).
- Where found: Prostate cancer: Open Targets association 0.58 with prostate cancer (MONDO_0008315); CIViC evidence names this disease; Lung cancer: CIViC evidence names this disease; Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; Neuroblastoma: IntOGen driver in 1 cohort (NBL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3493: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3493
- UniProt P43268: https://www.uniprot.org/uniprotkb/P43268/entry
- NCBI Gene 2118: https://www.ncbi.nlm.nih.gov/gene/2118
- Ensembl ENSG00000175832: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175832

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/etv4.json